Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) EBITDA (2021 - 2025)

Incannex Healthcare's EBITDA history spans 3 years, with the latest figure at -$6.8 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 7.93% to -$6.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$48.3 million, a 98.17% decrease, with the full-year FY2025 number at -$46.7 million, down 151.94% from a year prior.
  • EBITDA hit -$6.8 million in Q4 2025 for Incannex Healthcare, down from -$6.2 million in the prior quarter.
  • Over the last five years, EBITDA for IXHL hit a ceiling of -$1.2 million in Q3 2023 and a floor of -$31.3 million in Q2 2025.
  • Historically, EBITDA has averaged -$7.8 million across 3 years, with a median of -$6.2 million in 2024.
  • The widest YoY moves for EBITDA: up 40.8% in 2025, down 409.45% in 2025.
  • Tracing IXHL's EBITDA over 3 years: stood at -$4.3 million in 2023, then plummeted by 46.22% to -$6.3 million in 2024, then fell by 7.93% to -$6.8 million in 2025.
  • Business Quant data shows EBITDA for IXHL at -$6.8 million in Q4 2025, -$6.2 million in Q3 2025, and -$31.3 million in Q2 2025.